Molecular characterization of 103 ovarian serous and mucinous tumors. (Q53292665)

13 May 2018

title

Molecular characterization of 103 ovarian serous and mucinous tumors. (English)

1 reference

13 May 2018

author name string

Ildikó Vereczkey

1

1 reference

13 May 2018

Orsolya Serester

2

1 reference

13 May 2018

Judit Dobos

3

1 reference

13 May 2018

Mónika Gallai

4

1 reference

13 May 2018

Orsolya Szakács

5

1 reference

13 May 2018

Zoltán Szentirmay

6

1 reference

13 May 2018

Erika Tóth

7

1 reference

13 May 2018

publication date

7 December 2010

1 reference

13 May 2018

Pathology Oncology Research

published in

1 reference

13 May 2018

volume

17

1 reference

13 May 2018

issue

3

1 reference

13 May 2018

page(s)

551-559

1 reference

13 May 2018

https://scigraph.springernature.com/pub.10.1007/s12253-010-9345-8

exact match

0 references

cites work

Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas.

1 reference

https://api.crossref.org/works/10.1007%2FS12253-010-9345-8

Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-010-9345-8

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-010-9345-8

Borderline epithelial tumors of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-010-9345-8

Origins and molecular pathology of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-010-9345-8

Molecular pathology of epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-010-9345-8

Diverse tumorigenic pathways in ovarian serous carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-010-9345-8

Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-010-9345-8

Raf kinase as a target for anticancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-010-9345-8

Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-010-9345-8

In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-010-9345-8

Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-010-9345-8

Critical molecular abnormalities in high-grade serous carcinoma of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-010-9345-8

A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-010-9345-8

A candidate precursor to serous carcinoma that originates in the distal fallopian tube.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-010-9345-8

Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-010-9345-8

Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Müllerian system origin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-010-9345-8

Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-010-9345-8

Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-010-9345-8

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-010-9345-8

Molecular genetic analysis of ovarian serous cystadenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-010-9345-8

Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-010-9345-8

Clonal analysis favours a monoclonal origin for serous borderline tumours with peritoneal implants

21 January 2018

1 reference

12 December 2020

[Molecular pathology of epithelial ovarian neoplasias: from the phenotype-genotype correlation to new targets in diagnostics and therapy]

1 reference

12 December 2020

Allelic imbalance on chromosome 17p13 in borderline (low malignant potential) epithelial ovarian tumors

1 reference

12 December 2020

Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications

1 reference

12 December 2020

Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas

1 reference

12 December 2020

Microdissection-based mutational genotyping of serous borderline tumors of the ovary.

1 reference

12 December 2020

KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants

1 reference

12 December 2020

Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential

1 reference

12 December 2020

Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors

1 reference

12 December 2020

Germ line and somatic mutations of BRAF V599E in ovarian carcinoma

1 reference

12 December 2020

K-RAS mutations in ovarian and extraovarian lesions of serous tumors of borderline malignancy.

1 reference

12 December 2020

k-ras mutation may be an early event in mucinous ovarian tumorigenesis

1 reference

12 December 2020

Classification and Staging of Malignant Tumours in the Female Pelvis

1 reference

12 December 2020

Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors.

1 reference

12 December 2020

The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin

1 reference

12 December 2020

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

1 reference

12 December 2020

10.1007/S12253-010-9345-8

Identifiers

DOI

1 reference

13 May 2018

PubMed ID

21136228

1 reference

13 May 2018